Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction Muzaffar H. Qazilbash, Ali Imran.

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis Danielle H. Oh, Haocheng.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Caroline F. Morrison, Donna M

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation Jessica T. Stover,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Mats Remberger, Johan Törlén, Olle.

High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Anuj Mahindra, Brian Bolwell, Ronald.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma Katharina Lisenko,

Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Presentation transcript:

Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma Enrico Derenzini, Vittorio Stefoni, Roberto Maglie, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, Giulia Stefani, Stefano Fanti, Maria Rosa Motta, Riccardo Narducci, Lisa Argnani, Pier Luigi Zinzani Biology of Blood and Marrow Transplantation Volume 19, Issue 12, Pages 1695-1701 (December 2013) DOI: 10.1016/j.bbmt.2013.09.004 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 General study design. LVEF, left ventricular ejection fraction; PFT, pulmonary function test; PR, partial response. Biology of Blood and Marrow Transplantation 2013 19, 1695-1701DOI: (10.1016/j.bbmt.2013.09.004) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 HSC collection algorithm in the RIT group. LVEF, left ventricular ejection fraction; CHEMO, chemotherapy. Biology of Blood and Marrow Transplantation 2013 19, 1695-1701DOI: (10.1016/j.bbmt.2013.09.004) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (A) Impact of prior therapies (R-CHOP versus R-FM versus RIT) on the first PBSC mobilization attempt. (B) Impact of prior fludarabine versus R-CHOP exposure on the first PBSC mobilization attempt in the RIT group. (C) Impact of the number of prior therapies on the first PBSC mobilization attempt. *P < .05; **P < .01; ***P < .001. Biology of Blood and Marrow Transplantation 2013 19, 1695-1701DOI: (10.1016/j.bbmt.2013.09.004) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Time to ANC (≥500/μL) and PLT recovery (≥20,000/μL) in the chemotherapy (CHT) group (n = 87) compared with the RIT group (n = 10). (B) Time to ANC (≥500/μL) and PLT recovery (≥20,000/μL) in patients reinfused with <2.0 × 106/kg CD34+ cells (n = 9) compared with patients reinfused with >2.0 × 106/kg CD34+ cells (total n = 88). (C) Time to ANC (≥500/μL) and PLT recovery (≥20,000/μL) in the chemotherapy (CHT) group (n = 81) compared with the RIT group (n = 7) for patients reinfused with >2.0 × 106/kg CD34+ cells (total n = 88). Biology of Blood and Marrow Transplantation 2013 19, 1695-1701DOI: (10.1016/j.bbmt.2013.09.004) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions